# Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

> **NCT04497701** · NA · UNKNOWN · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 139 (estimated)

## Conditions studied

- Lymphoma
- Leukemia

## Interventions

- **DRUG:** PEG-rhG-CSF group
- **DRUG:** rhG-CSF group

## Key facts

- **NCT ID:** NCT04497701
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 139 (ESTIMATED)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04497701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04497701, "Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04497701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*